Revelation Biosciences, Inc. REVB
3.82 USD -0.44 (-10.43%)
Regular-session close
3.75 -0.07 -1.83%
After hours · Nov 16, 4:00 PM ET
3.71 Day range 4.00
3.08 52-week range 40.60
- YTD
- +19.37%
- 1 year
- +6.11%
Benzinga news
benzinga.com Revelation Biosciences Plans Accelerate Development Of Its Therapeutic Candidate Gemini; New Streamlined Phase 2a Study In Acute Kidney Injury To Deliver Topline Data In 2027 At Nearly 90% Lower Costs The strategy includes advancing a streamlined Phase 2a clinical study in patients with stage 2 or 3 acute kidney injury (AKI) to generate safety and efficacy data more rapidly and at substantially…
benzinga.com Revelation Biosciences Q3 EPS $(5.92) Beats $(6.16) Estimate Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(5.92) per share which beat the analyst consensus estimate of $(6.16) by 3.9 percent. This is a 88.04 percent increase over losses…
